Penumbra PE Ratio 2014-2022 | PEN
Current and historical p/e ratio for Penumbra (PEN) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Penumbra PE ratio as of August 10, 2022 is 724.86.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Penumbra PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-08-10 |
173.06 |
|
0.00 |
| 2022-06-30 |
124.52 |
$-0.42 |
0.00 |
| 2022-03-31 |
222.13 |
$-0.17 |
0.00 |
| 2021-12-31 |
287.32 |
$0.15 |
1915.47 |
| 2021-09-30 |
266.50 |
$0.91 |
292.86 |
| 2021-06-30 |
274.06 |
$0.43 |
637.35 |
| 2021-03-31 |
270.58 |
$-0.16 |
0.00 |
| 2020-12-31 |
175.00 |
$-0.44 |
0.00 |
| 2020-09-30 |
194.38 |
$-0.27 |
0.00 |
| 2020-06-30 |
178.82 |
$0.29 |
616.62 |
| 2020-03-31 |
161.33 |
$1.09 |
148.01 |
| 2019-12-31 |
164.27 |
$1.35 |
121.68 |
| 2019-09-30 |
134.49 |
$1.26 |
106.74 |
| 2019-06-30 |
160.00 |
$0.39 |
410.26 |
| 2019-03-31 |
147.01 |
$0.30 |
490.03 |
| 2018-12-31 |
122.20 |
$0.15 |
814.67 |
| 2018-09-30 |
149.70 |
$0.22 |
680.45 |
| 2018-06-30 |
138.15 |
$0.78 |
177.12 |
| 2018-03-31 |
115.65 |
$0.36 |
321.25 |
| 2017-12-31 |
94.10 |
$0.11 |
855.45 |
| 2017-09-30 |
90.30 |
$-0.22 |
0.00 |
| 2017-06-30 |
87.75 |
$-0.27 |
0.00 |
| 2017-03-31 |
83.45 |
$-0.21 |
0.00 |
| 2016-12-31 |
63.80 |
$-0.09 |
0.00 |
| 2016-09-30 |
75.99 |
$0.04 |
1899.75 |
| 2016-06-30 |
59.50 |
$0.11 |
540.91 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$6.042B |
$0.748B |
|
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
|
